Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
GOG-218 was a clinical trial overseen by the Gynaecological Oncology Group, looking at the benefit of combined therapy for almost 2000 ovarian cancer patients. Starting in 2005, the median follow up was 102 months.
As part of the trial the quality of life (QOL) was assessed using the Functional Assessment of Cancer Therapy – Ovarian*, which has a numeric score between 0 (low QOL) and 152 (high QOL). Measurements were taken before treatment, during chemo, and 6 months after chemo.
This study looks at the long-term survival (LTS) related to the patients QOL, with comparison between the group of long-term survivors (more than 8 years post diagnosis), and those whose survival was short, (less than 5 years).
Significant difference between the groups is noted with a 9-point increase in QOL, compared with baseline, equating to a 67% improvement in the odds for LTS. It is a small number; overall about 15% of women had LTS, with an increase to about 25% for those who improved QOL
* https://tinyurl.com/83c5yj4z
No comments:
Post a Comment